recent
year
emerg
highli
pathogen
avian
influenza
virus
transmiss
poultri
human
increas
global
travel
frequenc
creat
potenti
new
pandem
spread
sever
limit
strategi
prevent
treatment
highli
pathogen
avian
influenza
hpai
viru
includ
tradit
mean
segreg
sever
contemporari
prepar
antivir
drug
vaccin
antibodi
develop
current
two
class
medicin
avail
antivir
activ
influenza
viru
inhibitor
amantadin
rimantadin
neuraminidas
inhibitor
oseltamivir
zanamivir
unfortun
current
circul
strain
fulli
resist
neuraminidas
inhibitor
resist
inhibitor
clinic
neglig
far
like
detect
widespread
use
pandem
meanwhil
neuraminidas
inhibitor
may
improv
outcom
hpai
infect
patient
administ
earli
clinic
evid
enough
prove
certain
protect
efficaci
treat
sever
hpai
infect
patient
sever
strategi
use
develop
vaccin
protect
human
influenza
viru
infect
inactiv
subunit
live
attenu
vaccin
even
develop
success
largescal
innocul
vaccin
may
one
best
mean
control
spread
diseas
low
incid
new
case
hpai
viru
infect
passiv
immun
long
use
treatment
infecti
diseas
practic
administ
polyclon
immunoglobulin
hyperimmun
sera
anim
human
origin
centuri
old
histori
control
mani
viral
infect
hiv
rabi
hepat
b
viru
previou
studi
develop
equin
antisarscov
antihpai
viru
f
fragment
shown
effect
neutral
sarscov
viru
vitro
vivo
studi
specul
specif
antibodi
hpai
viru
may
altern
strategi
treatment
sever
hpai
viru
infect
patient
f
fragment
serum
igg
hors
immun
inactiv
influenza
whole
viru
antigen
prepar
thereaft
protect
efficaci
f
fragment
hpai
viru
investig
vitro
vivo
result
report
herein
provid
concret
experiment
data
clinic
studi
intern
immunopharmacolog
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
n
p
materi
method
wildtyp
influenza
viru
inocul
allanto
caviti
specif
pathogen
free
spf
embryon
egg
allanto
fluid
harvest
day
post
inocul
store
use
mdck
cell
cultur
dmem
medium
fb
cultur
flask
co
weekold
balbc
mice
approv
experi
institut
anim
welfar
committe
embryon
egg
anim
use
studi
provid
laboratori
anim
center
academi
militari
medic
scienc
oper
live
viru
perform
biosafeti
level
lab
purifi
inactiv
viru
antigen
prepar
accord
standard
techniqu
use
product
season
influenza
trival
inactiv
whole
viru
vaccin
briefli
inocul
allanto
caviti
spf
embryon
egg
harvest
day
post
inocul
inactiv
formaldehyd
biosafeti
level
lab
thereaft
inactiv
viru
concentr
purifi
pilot
scale
use
good
manufactur
practic
hengy
biolog
compani
shandong
puriti
harvest
viru
analyz
hplc
tosohaa
tokyo
japan
molecular
siev
matrix
store
use
year
old
healthi
brown
hors
kg
weight
detect
antibodi
influenza
viru
provid
chifeng
boen
pharmaci
co
ltd
inner
mongolia
china
inocul
subcutan
influenza
antigen
contain
mg
mg
mg
mg
ha
content
day
respect
inocul
ml
antigen
suspens
mix
equal
volum
adjuv
accord
direct
inject
sever
site
near
submandibular
inguin
lumph
node
two
week
post
last
immun
hors
bled
sera
detect
titer
influenza
viru
specif
antibodi
hemagglutin
inhibit
hi
assay
previous
describ
f
fragment
equin
serum
igg
hi
titer
prepar
shanghai
serum
biotech
co
ltd
shanghai
china
previous
describ
final
f
product
determin
lowri
method
hplc
respect
store
use
neutral
titer
f
fragment
influenza
viru
determin
vitro
previous
describ
brief
f
fragment
dilut
initi
highest
dose
twofold
serial
dilut
cultur
medium
mixtur
vv
viru
suspens
contain
live
viru
incub
h
f
viru
mixtur
ad
fresh
monolay
mdck
cell
plate
incub
day
co
atmospher
nd
equin
f
gave
neutral
calcul
use
reed
muench
method
express
reciproc
highest
f
dilut
bioactiv
unit
u
f
fragment
influenza
viru
determin
mous
model
f
fragment
dilut
twofold
serial
dilut
pb
mix
vv
viru
suspens
contain
tcid
ml
mous
model
live
viru
incub
h
f
viru
mixtur
infect
four
week
old
balbc
mice
day
mice
monitor
surviv
daili
day
bioactiv
unit
u
f
fragment
influenza
viru
express
reciproc
highest
dilut
protect
mice
ld
live
viru
therapeut
efficaci
equin
f
fragment
viru
mice
vivo
therapeut
efficaci
equin
f
fragment
viru
investig
mous
model
previous
describ
investig
doseefficaci
correl
four
week
old
balbc
mice
infect
ld
live
day
follow
ip
inject
f
fragment
four
dose
normal
hors
f
fragment
neg
control
day
post
infect
studi
timeefficaci
correl
four
week
old
balbc
mice
infect
ld
live
day
follow
ip
inject
f
fragment
differ
day
post
infect
mice
monitor
clinic
sign
bodi
weight
measur
daili
day
viral
load
infect
lung
mice
group
determin
previous
describ
euthanasia
day
data
analyz
use
graphpad
prism
softwar
surviv
data
analyz
kaplanmei
analysi
antibodi
viru
titer
compar
use
twotail
ttest
run
sdspage
gel
fig
sever
viral
major
antigen
band
viru
antigen
prepar
hengy
biolog
compani
correspond
na
protein
hplc
result
fig
show
puriti
two
week
last
immun
serum
harvest
chifeng
boen
pharmaci
co
ltd
hi
titer
equin
serum
antibodi
achiev
f
fragment
prepar
shanghai
serum
biotech
co
ltd
hi
titer
purifi
f
fragment
tabl
analyz
sdspage
f
fragment
migrat
one
kda
major
band
fig
puriti
f
fragment
reach
measur
folium
scan
method
fig
protein
concentr
equin
crude
serum
purifi
f
fragment
determin
lowri
method
compar
mgml
equin
crude
serum
protein
concentr
purifi
f
fragment
mgml
recoveri
rate
result
show
nd
equin
f
fragment
cultur
mdck
cell
bioactiv
unit
balbc
model
evalu
therapeut
doseefficaci
correl
equin
f
fragment
mice
receiv
equin
f
fragment
indic
dose
day
post
lethal
viru
challeng
data
show
equin
f
fragment
requir
confer
complet
protect
could
greatli
reliev
clinic
diseas
sign
lower
dose
show
partial
protect
fig
lower
dosag
f
fragment
also
show
increas
clinic
diseas
sign
howev
mice
succumb
infect
recov
almost
initi
weight
day
data
shown
investig
therapeut
timeefficaci
correl
equin
f
fragment
mice
receiv
equin
f
fragment
indic
day
post
lethal
viru
challeng
data
show
equin
f
fragment
use
sooner
prepar
inject
better
protect
efficaci
show
fig
viral
load
assay
confirm
result
exampl
f
fragment
use
two
day
post
lethal
viru
challeng
could
significantli
decreas
viral
load
infect
mice
lung
even
fold
compar
administr
normal
equin
f
fragment
control
data
shown
studi
confirm
specif
antibodi
could
improv
outcom
sever
hpai
viru
infect
case
mous
model
allow
host
immun
system
clear
remain
viru
provid
chanc
intervent
strategi
antivir
drug
vaccin
ultim
elimin
viru
host
even
though
sporad
case
infect
hpai
viru
hpai
viru
current
charact
high
mortal
could
fatal
jeopard
alreadi
infect
patient
life
mani
strategi
prevent
treatment
hpai
viru
infect
develop
almost
ceas
clinic
phase
low
morbid
diseas
low
commerci
profit
product
hpai
viru
suddenli
caus
pandem
human
uncertain
factor
arm
threat
especi
latent
phase
hpai
viru
infect
often
short
earli
symptom
usual
hard
distinguish
common
cold
delay
diagnosi
treatment
could
threat
patient
live
highli
purifi
antibodi
fragment
may
one
best
choic
control
diseas
drug
resist
hpai
variant
occurr
urgent
ideal
develop
antibodi
medicin
compar
longer
time
distanc
vaccin
elicit
protect
immun
healthi
host
highli
purifi
f
fragment
hpai
viru
could
provid
immedi
protect
regardless
immun
statu
host
meanwhil
still
long
way
go
bench
bedsid
variou
vaccin
hpai
viru
develop
highli
purifi
equin
f
fragment
prove
safe
use
adopt
humor
therapi
sever
diseas
mani
decad
mani
advantag
surmount
bottleneck
antibodi
yield
possess
broader
antigen
coverag
lower
likelihood
emerg
escap
mutant
compar
human
monoclon
antibodi
without
unavail
viru
mixtur
infect
four
week
old
balbc
mice
day
mice
monitor
surviv
daili
day
bioactiv
unit
u
f
fragment
influenza
viru
express
reciproc
highest
dilut
protect
mice
ld
live
viru
b
equin
f
dilut
antibodi
mix
tcid
viru
incub
h
mixtur
ad
monolay
mdck
cell
triplic
well
plate
incub
day
co
atmospher
nd
equin
f
gave
neutral
calcul
use
reed
muench
method
express
reciproc
highest
f
dilut
c
equin
f
test
titer
hi
antibodi
standard
method
use
ha
unit
viru
vbottom
micro
titer
plate
turkey
erythrocyt
hi
titer
express
reciproc
highest
f
dilut
convalesc
immun
human
plasma
meanwhil
equin
f
fragment
rel
econom
easili
avail
upon
request
take
hpai
viru
emerg
consider
prepar
f
fragment
hpai
viru
investig
protect
efficaci
vitro
vivo
qualiti
neutral
antibodi
influenc
treatment
efficaci
may
depend
quantiti
qualiti
innocul
antigen
f
fragment
accord
assay
puriti
innocul
antigen
f
fragment
respect
meet
request
bioprepar
china
bioactiv
f
bioprepar
vitro
vivo
satisfi
studi
mani
studi
humor
immun
respons
viru
infect
patient
indic
patient
longer
cours
ill
show
lower
neutral
antibodi
respons
higher
viru
load
longer
viru
discharg
time
patient
shorter
ill
durat
suggest
neutral
antibodi
patient
play
pivot
role
viru
clearanc
vivo
nt
know
doseefficaci
correl
f
bioprepar
hpai
viru
infect
address
question
evalu
therapeut
efficaci
differ
dose
f
fragment
viru
mice
result
show
even
f
innocul
within
two
day
post
infect
could
complet
protect
mice
diseas
upon
lethal
challeng
address
timeefficaci
correl
f
bioprepar
hpai
viru
infect
investig
therapeut
efficaci
f
fragment
viru
mice
differ
day
post
infect
data
indic
innocul
within
three
day
post
infect
f
could
greatli
improv
outcom
diseas
howev
innocul
day
post
infect
f
could
show
therapeut
efficaci
higher
dose
f
could
mayb
treat
diseas
later
phase
accordingli
level
protect
observ
decreas
viral
load
lung
although
complet
remark
consid
circul
antibodi
neutral
extracellular
hpai
viru
addit
protect
anim
show
lighter
patholog
chang
lung
data
shown
result
also
suggest
might
necessari
combin
passiv
antibodi
transfer
method
antivir
drug
reason
satur
concentr
antibodi
could
complet
neutral
viral
particl
summari
equin
f
fragment
use
studi
exhibit
excel
therapeut
effect
influenza
viru
provid
strong
experiment
support
clinic
larg
trial
author
declar
financi
commerci
conflict
interest
grate
hengy
biolog
compani
prepar
inactiv
whole
viru
influenza
antigen
chifeng
boen
